JPWO2022266045A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022266045A5 JPWO2022266045A5 JP2023576324A JP2023576324A JPWO2022266045A5 JP WO2022266045 A5 JPWO2022266045 A5 JP WO2022266045A5 JP 2023576324 A JP2023576324 A JP 2023576324A JP 2023576324 A JP2023576324 A JP 2023576324A JP WO2022266045 A5 JPWO2022266045 A5 JP WO2022266045A5
- Authority
- JP
- Japan
- Prior art keywords
- purines
- pyrimidines
- fluoro
- modified
- methyl modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211379P | 2021-06-16 | 2021-06-16 | |
| US63/211,379 | 2021-06-16 | ||
| PCT/US2022/033356 WO2022266045A1 (en) | 2021-06-16 | 2022-06-14 | Treatment of mtres1 related diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024523265A JP2024523265A (ja) | 2024-06-28 |
| JP2024523265A5 JP2024523265A5 (https=) | 2025-06-20 |
| JPWO2022266045A5 true JPWO2022266045A5 (https=) | 2025-06-20 |
Family
ID=84527350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023576324A Pending JP2024523265A (ja) | 2021-06-16 | 2022-06-14 | Ｍｔｒｅｓ１関連の疾患および障害の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240287518A1 (https=) |
| EP (1) | EP4355878A4 (https=) |
| JP (1) | JP2024523265A (https=) |
| KR (1) | KR20240034185A (https=) |
| CN (1) | CN117980478A (https=) |
| AU (1) | AU2022293669A1 (https=) |
| CA (1) | CA3221625A1 (https=) |
| IL (1) | IL309317A (https=) |
| MX (1) | MX2023015242A (https=) |
| WO (1) | WO2022266045A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024091874A1 (en) * | 2022-10-25 | 2024-05-02 | Empirico Inc. | Gene therapy treatment of mtres1 related diseases and disorders |
| WO2024091873A2 (en) * | 2022-10-25 | 2024-05-02 | Empirico Inc. | Small molecule treatment of mtres1 related diseases and disorders |
| WO2025158407A2 (en) * | 2024-01-26 | 2025-07-31 | Empirico Inc. | Treatment of mtres1 related diseases and disorders |
| WO2025226835A1 (en) * | 2024-04-24 | 2025-10-30 | Empirico Inc. | Gene therapy treatment of mtres1 related diseases and disorders |
| WO2025255269A1 (en) * | 2024-06-05 | 2025-12-11 | Empirico Inc. | Treatment of mtres1 related diseases and disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080279846A1 (en) * | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| US10004814B2 (en) * | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| US10287580B2 (en) * | 2014-03-14 | 2019-05-14 | The General Hospital Corporation | Molecular re-engineering of excitation-inhibition balance in memory circuits |
| PH12018501207B1 (en) * | 2015-12-21 | 2024-02-23 | Novartis Ag | Compositions and methods for decreasing tau expression |
| EP4004206A1 (en) * | 2019-07-23 | 2022-06-01 | University of Rochester | Targeted rna cleavage with crispr-cas |
-
2022
- 2022-06-14 EP EP22825630.1A patent/EP4355878A4/en active Pending
- 2022-06-14 KR KR1020247000882A patent/KR20240034185A/ko active Pending
- 2022-06-14 US US18/568,758 patent/US20240287518A1/en active Pending
- 2022-06-14 JP JP2023576324A patent/JP2024523265A/ja active Pending
- 2022-06-14 AU AU2022293669A patent/AU2022293669A1/en active Pending
- 2022-06-14 WO PCT/US2022/033356 patent/WO2022266045A1/en not_active Ceased
- 2022-06-14 IL IL309317A patent/IL309317A/en unknown
- 2022-06-14 CA CA3221625A patent/CA3221625A1/en active Pending
- 2022-06-14 CN CN202280056109.XA patent/CN117980478A/zh active Pending
- 2022-06-14 MX MX2023015242A patent/MX2023015242A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113166759B (zh) | 经化学修饰的RNAi构建体及其用途 | |
| AU2018202014B2 (en) | Rna interference in dermal and fibrotic indications | |
| AU2017210726B2 (en) | Branched oligonucleotides | |
| CN111373043B (zh) | 用于降低snca表达的化合物和方法 | |
| JP2022526419A (ja) | 中枢神経系における遺伝子発現を阻害するための組成物及び方法 | |
| JP2025063137A (ja) | Ｓｍｎ２の調節のための化合物及び方法 | |
| RS63836B1 (sr) | Proizvodi i sastavi | |
| JP2021533804A5 (https=) | ||
| BR112015027369B1 (pt) | compostos compreendendo um oligonucleotídeo modificado e um grupo de conjugado, composição compreendendo os referidos compostos e usos dos mesmos | |
| JP2023539341A (ja) | Ｄｕｘ４阻害剤およびその使用方法 | |
| JPWO2020132227A5 (https=) | ||
| TW202246502A (zh) | 抑制中樞神經系統中的基因表現之組成物及方法 | |
| JP2020529197A5 (https=) | ||
| JPWO2020041769A5 (https=) | ||
| CN119403927A (zh) | 用于抑制跨膜丝氨酸蛋白酶6（tmprss6）表达的组合物和方法 | |
| JPWO2022266045A5 (https=) | ||
| JP2023530072A (ja) | Ｐｍｐ２２を調節するための化合物及び方法 | |
| CN119630791A (zh) | 用于抑制snca表达的组合物和方法 | |
| JPWO2022031847A5 (https=) | ||
| WO2023164656A2 (en) | Compounds and methods for modulating atn1 expression | |
| TW202128999A (zh) | 用於減少spdef表現之化合物及方法 | |
| EP4446414A1 (en) | Antisense oligonucleotide complex | |
| JPWO2021150969A5 (https=) | ||
| JPWO2022182864A5 (https=) | ||
| TW202340462A (zh) | 靶定中樞神經系統的寡樹突細胞之脂質結合物 |